Skip to NavigationSkip to content

UAE reveals 86% effiacy for Sinopharm's COVID-19 vaccine

Published on 10/12/20 at 01:20pm

The Health Ministry of the United Arab Emirates has unveiled the first known efficacy data for the COVID-19 vaccine candidate from Chinese state-owned pharmaceutical firm Sinopharm, painting a similarly strong picture to those seen from other vaccine manufacturers including Moderna and Pfizer/BioNTech in recent weeks.

Phase 3 trials for the therapy kicked off in July this year, comprising 31,000 participants of 125 different nationalities. According to interim analysis of the trials, the vaccine showed an efficacy rate of 86%, with a “99% seroconversion rate of neutralising antibody and 100% effectiveness in preventing moderate and severe cases of the disease.”

This is the first publication of any efficacy findings associated with Sinopharm’s vaccine, and while it paints a promising picture, details were thin; the analysis identified “no serious safety concerns” with the candidate, but did not reveal information on the prevalence of side-effects or how many participants received either the vaccine or a control therapy.

The therapy has been approved for emergency use in the UAE since September for frontline healthcare staff, and nearly 100,000 UAE citizens have already received it on a voluntary basis.  

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches